{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T22:04:04Z","timestamp":1778018644508,"version":"3.51.4"},"reference-count":28,"publisher":"The Society for Free Radical Research Japan","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Biochem. Nutr."],"published-print":{"date-parts":[[2019]]},"DOI":"10.3164\/jcbn.18-92","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T17:38:55Z","timestamp":1551893935000},"page":"265-270","source":"Crossref","is-referenced-by-count":30,"title":["Capabilities of fecal calprotectin and blood biomarkers as surrogate endoscopic markers according to ulcerative colitis disease type"],"prefix":"10.3164","volume":"64","author":[{"given":"Hiroki","family":"Sonoyama","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, Shimane University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kousaku","family":"Kawashima","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Shimane University Hospital"},{"name":"Inflammatory Bowel Disease Center, Shimane University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunji","family":"Ishihara","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Shimane University Hospital"},{"name":"Inflammatory Bowel Disease Center, Shimane University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Kotani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Shimane University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Fukuba","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Shimane University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Oka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Shimane University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryusaku","family":"Kusunoki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Shimane University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasumasa","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Shimane University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Mishima","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Shimane University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Oshima","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Shimane University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Moriyama","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Shimane University Hospital"},{"name":"Cancer Center, Shimane University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Yuki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Shimane University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Onishi","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Matsue Seikyo General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikazu","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Shimane University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1739","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 2012; 6: 965\u2013990.","DOI":"10.1016\/j.crohns.2012.09.003"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 2012; 61: 1619\u20131635.","DOI":"10.1136\/gutjnl-2012-302830"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Sugihara K, Masuda M, Nakao M, et al. Dietary phosphate exacerbates intestinal inflammation in experimental colitis. J Clin Biochem Nutr 2017; 61: 91\u201399.","DOI":"10.3164\/jcbn.16-117"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462\u20132476.","DOI":"10.1056\/NEJMoa050516"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med 2014; 160: 704\u2013711.","DOI":"10.7326\/M13-2403"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Armuzzi A, Pugliese D, Danese S, et al. Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. Inflamm Bowel Dis 2014; 20: 1368\u20131374.","DOI":"10.1097\/MIB.0000000000000115"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257\u2013265.","DOI":"10.1053\/j.gastro.2011.10.032"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Ogata H, Kato J, Hirai F, et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis 2012; 18: 803\u2013808.","DOI":"10.1002\/ibd.21853"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Peyrin-Biroulet L, Ferrante M, Magro F, et al.; Scientific Committee of the European Crohn\u2019s and Colitis Organization. Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis 2011; 5: 477\u2013483.","DOI":"10.1016\/j.crohns.2011.06.009"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Meucci G, Fasoli R, Saibeni S, et al. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study. Inflamm Bowel Dis 2012; 18: 1006\u20131010.","DOI":"10.1002\/ibd.21838"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Fr\u00f8slie KF, Jahnsen J, Moum BA, Vatn MH; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412\u2013422.","DOI":"10.1053\/j.gastro.2007.05.051"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 2008; 57: 1518\u20131523.","DOI":"10.1136\/gut.2007.146357"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Osada T, Ohkusa T, Okayasu T, et al. Correlations among total colonoscopic findings, clinical, symptoms, and laboratory markers in ulcerative colitis. J Gastroenterol Hepatol 2008; 23 Suppl 2: S262\u2013S267.","DOI":"10.1111\/j.1440-1746.2008.05413.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Lok KH, Ng CH, Hung HG, Li KF, Li KK, Szeto ML. Correlation of serum biomarkers with clinical severity and mucosal inflammation in Chinese ulcerative colitis patients. J Dig Dis 2008; 9: 219\u2013224.","DOI":"10.1111\/j.1751-2980.2008.00350.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006; 55: 426\u2013431.","DOI":"10.1136\/gut.2005.069476"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Kawashima K, Ishihara S, Yuki T, et al. Fecal calprotectin level correlated with both endoscopic severity and disease extent in ulcerative colitis. BMC Gastroenterol 2016; 16: 47.","DOI":"10.1186\/s12876-016-0462-z"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Schoepfer AM, Beglinger C, Straumann A, Trummler M, Renzulli P, Seibold F. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 2009; 15: 1851\u20131858.","DOI":"10.1002\/ibd.20986"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis 2013; 19: 332\u2013341.","DOI":"10.1097\/MIB.0b013e3182810066"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749\u2013753.","DOI":"10.1136\/gut.2005.082909"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Rendek Z, Falk M, Grodzinsky E, et al. Effect of oral diclofenac intake on faecal calprotectin. Scand J Gastroenterol 2016; 51: 28\u201332.","DOI":"10.3109\/00365521.2015.1066421"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Iguchi M, Kakimoto K, Kuramoto T, et al. Effect of egualen sodium hydrate on small-intestinal mucosal damage induced by low-dose aspirin: a prospective randomized clinical trial. J Clin Biochem Nutr 2018; 62: 174\u2013178.","DOI":"10.3164\/jcbn.17-46"},{"key":"22","unstructured":"22 Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625\u20131629."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Barreiro-de Acosta M, Vallejo N, de la Iglesia D, et al. Evaluation of the risk of relapse in ulcerative colitis according to the degree of mucosal healing (Mayo 0 vs 1): a longitudinal cohort study. J Crohns Colitis 2016; 10: 13\u201319.","DOI":"10.1093\/ecco-jcc\/jjv158"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24 Fukuda T, Naganuma M, Sugimoto S, et al. Efficacy of therapeutic intervention for patients with an ulcerative colitis Mayo endoscopic score of 1. Inflamm Bowel Dis 2018. DOI: 10.1093\/ibd\/izy300","DOI":"10.1093\/ibd\/izy300"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Nakarai A, Hiraoka S, Takahashi S, et al. Simultaneous measurements of faecal calprotectin and the faecal immunochemical test in quiescent ulcerative colitis patients can stratify risk of relapse. J Crohns Colitis 2018; 12: 71\u201376.","DOI":"10.1093\/ecco-jcc\/jjx118"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Lasson A, \u00d6hman L, Stotzer PO, et al. Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: a prospective, randomized, controlled study. United European Gastroenterol J 2015; 3: 72\u201379.","DOI":"10.1177\/2050640614560785"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Nakarai A, Kato J, Hiraoka S, et al. An elevated platelet count increases the risk of relapse in ulcerative colitis patients with mucosal healing. Gut Liver 2018; 12: 420\u2013425.","DOI":"10.5009\/gnl17236"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Lobat\u00f3n T, Rodr\u00edguez-Moranta F, Lopez A, S\u00e1nchez E, Rodr\u00edguez-Alonso L, Guardiola J. A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis. Inflamm Bowel Dis 2013; 19: 1034\u20131042.","DOI":"10.1097\/MIB.0b013e3182802b6e"}],"container-title":["Journal of Clinical Biochemistry and Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jcbn\/64\/3\/64_18-92\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T23:40:51Z","timestamp":1556926851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jcbn\/64\/3\/64_18-92\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.3164\/jcbn.18-92","relation":{},"ISSN":["0912-0009","1880-5086"],"issn-type":[{"value":"0912-0009","type":"print"},{"value":"1880-5086","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}